1.Unilateral Keratosis Lichenoides Chronica.
Nam Joon CHO ; Sungbin IM ; Seung Hun LEE
Annals of Dermatology 1994;6(1):78-80
Keratosis lichenoides chronica is rare chronic dermatosis characterized by progressive development of licheniod papulonodules especially on the extremities and trunk. A 15-year-old male patient had erythematous to violaceous scaly patches and plaques on the left side of trunk and lower extremity along Blaschko's lines. Clinical and histologic findings were compatible with keratosis lichenoides chronica showing unilateral distribution.
Adolescent
;
Extremities
;
Humans
;
Keratosis*
;
Lower Extremity
;
Male
;
Skin Diseases
2.Artificial Reproduction of Lupus Erythematosus by Provocative Phototesting.
Young Ho CHO ; Seung Kyung HANN ; Yoon Kee PARK ; Min Seok SONG ; Sungbin IM
Annals of Dermatology 1993;5(2):105-108
Sunlight is one of the well-established factors which play key roles in the induction and exacerbation of lupus erythematosus. In two patients of discoid lupus erythematosus, we have experimentally reproduced skin lesions by provocative phototesting. Both UVA (100 joules/cm²) and UVB (80 millijoules/cm²) radiation induced the skin lesions. The reproduced skin lesions were clinically and histopathologically consistent with lupus erythematosus.
Humans
;
Lupus Erythematosus, Discoid
;
Reproduction*
;
Skin
;
Sunlight
3.The skin concentration and minimal phototoxic dose following administration of phototoxic drugs as a function of time.
Yoon Kee PARK ; Moo Yon CHO ; Seung Kyung HANN ; Sungbin IM
Korean Journal of Dermatology 1991;29(5):588-601
No abstract available.
Skin*
4.Extracorporeal Life Support in Adult Patients with Hematologic Malignancies and Acute Circulatory and/or Respiratory Failure
Sungbin CHO ; Won Chul CHO ; Ju Yong LIM ; Pil Je KANG
The Korean Journal of Thoracic and Cardiovascular Surgery 2019;52(1):25-31
BACKGROUND: The primary goal of this study was to characterize the clinical outcomes of adult patients with hematologic malignancies (HM) who were treated with extracorporeal membrane oxygenation (ECMO) support when conventional treatments failed. METHODS: In this retrospective, observational study at a tertiary medical center, we reviewed the clinical course of 23 consecutive patients with HM requiring ECMO who were admitted to the intensive care unit at Asan Medical Center from March 2010 to April 2015. RESULTS: A total of 23 patients (8 female; median age, 44 years; range, 29–51 years) with HM and severe acute circulatory and/or respiratory failure received ECMO therapy during the study period. Fourteen patients received veno-arterial ECMO, while 9 patients received veno-venous ECMO. The median ECMO duration was 104.7 hours (range, 37.1–221 hours). Nine patients were successfully weaned from ECMO. The in-hospital mortality rate was 91.1% (21 of 23). There were complications in 3 patients (cannulation site bleeding, limb ischemia, and gastrointestinal bleeding). CONCLUSION: ECMO is a useful treatment for patients with circulatory and/or pulmonary failure. However, in patients with HM, the outcomes of ECMO treatment results were very poor, so it is advisable to carefully decide whether to apply ECMO to these patients.
Adult
;
Chungcheongnam-do
;
Extracorporeal Membrane Oxygenation
;
Extremities
;
Female
;
Hematologic Neoplasms
;
Hemorrhage
;
Hospital Mortality
;
Humans
;
Intensive Care Units
;
Ischemia
;
Mortality
;
Observational Study
;
Respiratory Insufficiency
;
Retrospective Studies
5.Extracorporeal Life Support in Adult Patients with Hematologic Malignancies and Acute Circulatory and/or Respiratory Failure
Sungbin CHO ; Won Chul CHO ; Ju Yong LIM ; Pil Je KANG
The Korean Journal of Thoracic and Cardiovascular Surgery 2019;52(1):25-31
BACKGROUND:
The primary goal of this study was to characterize the clinical outcomes of adult patients with hematologic malignancies (HM) who were treated with extracorporeal membrane oxygenation (ECMO) support when conventional treatments failed.
METHODS:
In this retrospective, observational study at a tertiary medical center, we reviewed the clinical course of 23 consecutive patients with HM requiring ECMO who were admitted to the intensive care unit at Asan Medical Center from March 2010 to April 2015.
RESULTS:
A total of 23 patients (8 female; median age, 44 years; range, 29–51 years) with HM and severe acute circulatory and/or respiratory failure received ECMO therapy during the study period. Fourteen patients received veno-arterial ECMO, while 9 patients received veno-venous ECMO. The median ECMO duration was 104.7 hours (range, 37.1–221 hours). Nine patients were successfully weaned from ECMO. The in-hospital mortality rate was 91.1% (21 of 23). There were complications in 3 patients (cannulation site bleeding, limb ischemia, and gastrointestinal bleeding).
CONCLUSION
ECMO is a useful treatment for patients with circulatory and/or pulmonary failure. However, in patients with HM, the outcomes of ECMO treatment results were very poor, so it is advisable to carefully decide whether to apply ECMO to these patients.
6.Chylous Manifestations and Management of Gorham-Stout Syndrome
Sungbin CHO ; Seung Ri KANG ; Beom Hee LEE ; Sehoon CHOI
The Korean Journal of Thoracic and Cardiovascular Surgery 2019;52(1):44-46
Gorham-Stout disease (GSD) was first described by Gorham and colleagues in 1954, but its precise mechanism and cause remain to be elucidated. In this condition, voluminous and potentially fatal chylous effusions into the thorax can occur. Herein, we describe a case of GSD in which the patient presented with massive pleural effusions and mottled osteolytic bone lesions. We performed multiple operations, including thoracic duct ligation using video-assisted thoracoscopic surgery and thoracotomic decortication, but these procedures did not succeed in preventing recurrent pleural effusion and chest wall lymphedema. After administering sirolimus (0.8 mg/m2, twice a day) and propranolol (40 mg, twice a day), the process of GSD in this patient has been controlled for more than 2 years.
Chylothorax
;
Humans
;
Ligation
;
Lymphedema
;
Osteolysis, Essential
;
Pleural Effusion
;
Propranolol
;
Sirolimus
;
Thoracic Duct
;
Thoracic Surgery, Video-Assisted
;
Thoracic Wall
;
Thorax
7.Chylous Manifestations and Management of Gorham-Stout Syndrome
Sungbin CHO ; Seung Ri KANG ; Beom Hee LEE ; Sehoon CHOI
The Korean Journal of Thoracic and Cardiovascular Surgery 2019;52(1):44-46
Gorham-Stout disease (GSD) was first described by Gorham and colleagues in 1954, but its precise mechanism and cause remain to be elucidated. In this condition, voluminous and potentially fatal chylous effusions into the thorax can occur. Herein, we describe a case of GSD in which the patient presented with massive pleural effusions and mottled osteolytic bone lesions. We performed multiple operations, including thoracic duct ligation using video-assisted thoracoscopic surgery and thoracotomic decortication, but these procedures did not succeed in preventing recurrent pleural effusion and chest wall lymphedema. After administering sirolimus (0.8 mg/m2, twice a day) and propranolol (40 mg, twice a day), the process of GSD in this patient has been controlled for more than 2 years.